Department of Endemic Medicine and Hepatogastroenterology, Kasr Alainy, Cairo University, Cairo, Egypt.
School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine, BT52 1SA, Northern Ireland, United Kingdom.
Autoimmun Rev. 2021 Nov;20(11):102941. doi: 10.1016/j.autrev.2021.102941. Epub 2021 Sep 9.
Although vaccination represents the most promising way to stop or contain the coronavirus disease 2019 (COVID-19) pandemic and safety and effectiveness of available vaccines were proven, a small number of individuals who received anti-SARS-CoV-2 vaccines developed a prothrombotic syndrome. Vaccine-induced immune thrombotic thrombocytopenia (VITT) can be triggered by the adenoviral vector-based vaccine, whereas lipid nanoparticle-mRNA-based vaccines can induce rare cases of deep vein thrombosis (DVT). Although the main pathogenic mechanisms behind this rare phenomenon have not yet been identified, both host and vaccine factors might be involved, with pathology at least in part being related to the vaccine-triggered autoimmune reaction. In this review, we are considering some aspects related to pathogenesis, major risk factors, as well as peculiarities of diagnosis and treatment of this rare condition.
尽管疫苗接种代表了阻止或控制 2019 年冠状病毒病(COVID-19)大流行的最有希望的方法,并且已证明现有疫苗的安全性和有效性,但少数接种抗 SARS-CoV-2 疫苗的人出现了促血栓形成综合征。腺病毒载体疫苗可引发疫苗诱导的免疫性血栓性血小板减少症(VITT),而基于脂质纳米颗粒的 mRNA 疫苗可引起罕见的深静脉血栓形成(DVT)。尽管这种罕见现象背后的主要发病机制尚未确定,但宿主和疫苗因素都可能参与其中,至少部分病理学与疫苗引发的自身免疫反应有关。在这篇综述中,我们考虑了与发病机制、主要危险因素以及这种罕见疾病的诊断和治疗特点相关的一些方面。